Idenix CEO Renaud has plan to recover from clinical setbacks, company's stock rallies
This article was originally published in Scrip
Executive Summary
Idenix Pharmaceuticals CEO Ron Renaud admits his company has had a “tough track record” developing drugs over the past couple of years.